MCM
TRDA icon

MAI Capital Management’s Entrada Therapeutics TRDA Stock Holding History

MAI Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$682 Buy
+54
New +$619 ﹤0.01% 4309

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAI Capital Management's TRDA Position: Q1 2026 in Review

MAI Capital Management opened a new position in Entrada Therapeutics (TRDA) in Q1 2026: 54 shares worth $682. The stake represents ﹤0.01% of the portfolio and ranks #4309 among its holdings.

120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • MAI Capital Management held 54 shares of Entrada Therapeutics worth $682 as of Q1 2026.
  • Entrada Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Entrada Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4309 holding.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.